Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 16/20 | 0.65 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.62 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.62 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.62 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.62 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.62 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.62 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.62 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.62 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.62 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.59 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.59 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.59 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.59 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.59 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.59 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.59 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.59 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.59 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL970432 | 0.98 | CCNB2 (0.64) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| Hydrochloric Acid SCHEMBL3769079 | 0.98 | CCNB2 (0.64) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL30939928 | 0.98 | CCNB2 (0.68) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL177685 | 0.98 | CCNB2 (0.68) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| Acetamide SCHEMBL28491482 | 0.90 | DYRK1A (0.64) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| Propionamide SCHEMBL28500673 | 0.87 | DYRK1A (0.60) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL6456554 | 0.86 | MAOA (0.61) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| Butyramide SCHEMBL28501063 | 0.85 | DYRK1A (0.57) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| Norharmane SCHEMBL1626892 | 0.84 | MAOA (0.63) | CCNB2CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL15236149 | 0.82 | CCNB2 (0.71) | CCNB2CDK1CCNB1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200095627-A1 | MOLECULAR SENSORS AND USES THEREOF | NEW YORK UNIVERSITY | 2020-03-26 | — | — | US | claimed |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2025-08-14 | — | — | US | disclosed |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-29 | — | — | US | disclosed |
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2024-04-09 | — | — | US | disclosed |
| EP-4324832-A2 | IMMUNOMODULATORY COMPOUNDS AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | AC BioScience SA (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20230355749-A1 | Immunomodulatory Compounds And Use Thereof For The Treatment And/Or Prevention Of Infectious Diseases | AC BIOSCIENCE SA (CH) | 2023-11-09 | — | — | US | disclosed |
| CN-116406286-A | Immunomodulatory compounds and their use for the treatment and/or prophylaxis of infectious diseases | AC生命科学有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-115916195-A | Therapeutic agents and uses thereof | 安科生命科学有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-107106519-B | Therapeutic agent for human | 安克生命科学公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-115569136-A | Therapeutic agent for human | 安克生命科学公司 | 2023-01-06 | — | — | CN | disclosed |
| EP-2276345-A1 | SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR | The Regents of the University of California (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100168128-A1 | SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-01 | — | — | US | disclosed |
| US-7696227-B2 | Small-molecule inhibitors of the androgen receptor | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-04-13 | — | — | US | disclosed |
| WO-2009132307-A1 | SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090269772-A1 | SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST | THERASIS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20080293766-A1 | SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008128100-A1 | SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-10-23 | — | — | WO | disclosed |
| US-7410975-B2 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| WO-2007117466-A2 | CELASTROL, GEDUNIN, AND DERIVATIVES THEREOF AS HSP90 INHIBITORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20050119273-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119273-A1 | Small molecule toll-like receptor (TLR) antagonists | TLR3, TLR8, TLR7 | MAOA 4379/4885ADRA2A 1099/4885ADRA2B 1012/4885 |
| US-20100168128-A1 | SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR | AR, GNRHR, FSHR | MAOA 2630/4885ADRA2A 687/4885ADRA2B 544/4885 |
| US-11951099-B2 | Methods for treating plasma cell neoplasm with human therapeutic agents | MCL1, CD44, INMT | MAOA 2074/4885ADRA2A 2676/4885ADRA2B 3342/4885 |
| US-20240285592-A1 | HUMAN THERAPEUTIC AGENTS | INMT, NLN, MYC | MAOA 590/4885ADRA2A 2592/4885ADRA2B 3593/4885 |
| US-20080293766-A1 | SMALL-MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR | AR, GNRHR, FSHR | MAOA 2630/4885ADRA2A 687/4885ADRA2B 544/4885 |
| US-20230355749-A1 | Immunomodulatory Compounds And Use Thereof For The Treatment And/Or Prevention Of Infectious Diseases | CD14, TLR9, TLR3 | MAOA 2392/4885ADRA2A 4290/4885ADRA2B 4098/4885 |
| US-20250255853-A1 | HUMAN THERAPEUTIC AGENTS | HASPIN, TIPARP, SHARPIN | MAOA 1479/4885ADRA2A 1261/4885ADRA2B 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.